Voyager Digital (OTCMKTS:VYGVF) and SWEDISH ORPHAN/S (OTCMKTS:SWTUY) Financial Survey

Profitability

This table compares Voyager Digital and SWEDISH ORPHAN/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Voyager Digital	-12.60%	-23.41%	-1.16%
SWEDISH ORPHAN/S	25.75%	29.63%	18.74%

Insider and Institutional Ownership

0.7% of Voyager Digital shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Voyager Digital and SWEDISH ORPHAN/S”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Digital	$175.06 million	0.00	-$51.49 million	($0.30)	N/A
SWEDISH ORPHAN/S	$763.19 million	8.71	$134.73 million	$0.50	48.76

SWEDISH ORPHAN/S has higher revenue and earnings than Voyager Digital. Voyager Digital is trading at a lower price-to-earnings ratio than SWEDISH ORPHAN/S, indicating that it is currently the more affordable of the two stocks.

Summary

SWEDISH ORPHAN/S beats Voyager Digital on 7 of the 8 factors compared between the two stocks.

About Voyager Digital

Voyager Digital Ltd., through its subsidiaries, operates as a crypto asset brokerage firm primarily in the United States and Canada. It operates a digital platform that enables users to buy and sell crypto assets across multiple centralized marketplaces in one account. The company was formerly known as Voyager Digital (Canada) Ltd. and changed its name to Voyager Digital Ltd. in July 2020. The company was founded in 2018 and is headquartered in New York, New York.

About SWEDISH ORPHAN/S

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B. It also provides Orfadin for the treatment of hereditary tyrosinaemia type 1; and Kineret for the treatment of auto inflammatory condition, as well as Xiapex to treat Dupuytren's contracture and Peyronie's disease. In addition, the company manufactures drug substance for ReFacto AF; and develops BIVV001 and BIVV002 for the treatment of hemophilia. It operates in Sweden, the Middle East, North Africa, Russia, North America, other European countries, and internationally. The company has an agreement with Bioverativ for the development and commercialization of Elocta and Alprolix, as well as XTEN-programs. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.